Develops simufilam, an oral drug candidate for tuberous sclerosis complex-related epilepsy and other disorders associated with filamin A.
10-K for FY2025, filed Mar 12, 2026Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas. Our mission…View ↗
Our lead therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of…View ↗
Simufilam is intended to modulate the activity of a protein called filamin A, which regulates diverse aspects of neuronal cell development.…View ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
−$10.7MView ↗
8-K, filed Sep 22, 2026
During the course of the clinical hold, the Company completed key trial-readiness activities, including engaging a leading clinical…View ↗
8-K, filed Sep 18, 2026
In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until March 16, 2027, to regain…View ↗
A shift in disease focus
The older report described simufilam as being studied for Alzheimer’s disease and also listed a blood test candidate for detecting Alzheimer’s. The latest report focuses on simufilam for TSC-related epilepsy and other conditions associated with filamin A.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 12, 2026Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat…View ↗
We currently have two biopharmaceutical assets under development:View ↗
our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer’s disease from a…View ↗
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas. Our mission…View ↗
Our lead therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of…View ↗
Simufilam is intended to modulate the activity of a protein called filamin A, which regulates diverse aspects of neuronal cell development.…View ↗
Competes with Vigabatrin, Levetiracetam, Valproate, Clobazam, Afinitor Disperz, and Epidiolex
10-K for FY2025, filed Mar 12, 2026With respect to TSC-related epilepsy, two pharmacological treatment categories are approved for this patient population. The first category…View ↗
Loading...